All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2004-000304-41 | A MULTICENTRE, 1:1 RANDOMISED, DOUBLE BLIND, TWO ARM PARALLEL GROUP STUDY TO EVALUATE AND COMPARE THE EFFICACY AND SAFETY OF MODIFIED RELEASE TACROLIMUS FK506E (MR4) VERSUS TACROLIMUS FK506 IN COMBINA... | 2006-12-28 | due-trials |
| Reported results | 2004-000306-46 | A MULTICENTRE, 1:1 RANDOMISED, DOUBLE BLIND, TWO ARM PARALLEL GROUP STUDY TO EVALUATE AND COMPARE THE EFFICACY AND SAFETY OF MODIFIED RELEASE TACROLIMUS FK506E (MR4) VERSUS TACROLIMUS FK506 IN COMBINA... | 2006-02-27 | due-trials |
| Reported results | 2004-000457-34 | A MULTICENTRE, RANDOMISED, OPEN CLINICAL STUDY TO COMPARE THE EFFICACY AND SAFETY OF A COMBINATION THERAPY OF TACROLIMUS WITH SIROLIMUS VERSUS TACROLIMUS WITH MYCOPHENOLATE MOFETIL IN KIDNEY TRANSPLAN... | 2006-08-11 | due-trials |
| Reported results | 2004-000984-81 | A PHASE III PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, TOLERANCE AND EFFICACY STUDY OF RSD1235 IN SUBJECTS WITH ATRIAL FIBRILLATION OR ATRIAL FLUTTER | 2005-07-30 | due-trials |
| Reported results | 2004-001491-39 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE STUDY OF MICAFUNGIN (FK463) VERSUS CASPOFUNGIN AS ANTIFUNGAL TREATMENT IN PATIENTS WITH INVASIVE CANDIDIASIS OR CANDIDEMIA | 2006-04-27 | due-trials |
| Reported results | 2004-001617-34 | AN OPEN, RANDOMISED, MULTICENTRE, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF TACROLIMUS AND MINIMAL STEROIDS IN COMBINATION WITH EITHER A MONOCLONAL ANTI-IL2R ANTIBODY (DACLIZUMAB) OR ... | 2008-09-15 | due-trials |
| Reported results | 2004-003880-61 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE POTENTIAL EFFICACY, SAFETY AND TOLERABILITY OF DIFFERENT ORAL DOSES OF YM060 IN PATIENTS WITH DIARRHEA-PREDOMINANT IRRITABLE BOW... | 2005-12-19 | due-trials |
| Reported results | 2004-004561-14 | AN OPEN, RANDOMISED, MULTICENTRE, EXPLORATORY CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF TACROLIMUS IN COMBINATION WITH MONOCLONAL ANTI-IL2R ANTIBODIES OR STEROIDS IN HCV POSITIVE PATIENTS U... | 2008-06-15 | due-trials |
| Reported results | 2005-000914-11 | A Phase II, Multicenter, Open-Label Study of YM155 in Patients With Advanced Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC) Who Have Failed One or Two Prior Lines of Therapy, at Least One of Whi... | 2007-04-11 | due-trials |
| Reported results | 2005-001102-31 | A phase II, open-label, multi-centre study to assess the effect of single and multiple oral doses (1 mg, 2 mg, and 3 mg) of everolimus on the pharmacokinetics of tacrolimus in stable renal transplant ... | 2007-07-31 | due-trials |
| Reported results | 2005-001348-22 | AN OPEN, RANDOMISED, MULTICENTRE CLINICAL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF STEROID WITHDRAWAL WITH TACROLIMUS, MYCOPHENOLATE MOFETIL AND DACLIZUMAB AGAINST TACROLIMUS, MYCOPHENOLATE MOF... | 2008-02-25 | due-trials |
| Reported results | 2005-001627-11 | A randomized, double-blind, placebo-controlled study to assess the effect of Tamsulosin OCAS 0.4 mg tablets, once daily on nocturia, compared to placebo, in patients with lower urinary tract symptoms ... | 2007-04-10 | due-trials |
| Reported results | 2005-002256-17 | A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multi-Center Dose Ranging Study with the Beta-3 AGONist YM178 in Patients with Symptomatic Overactive Bladder (DRAGON) | 2007-04-23 | due-trials |
| Reported results | 2005-002456-18 | A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF A FOUR-WEEK TREATMENT WITH YM758 IN SUBJECTS WITH STABLE ANGINA. | 2006-12-01 | due-trials |
| Reported results | 2005-002457-41 | Direct Factor Xa inhibitor YM150 for prevention of venous thromboembolism in patients undergoing elective total hip replacement. A double blind, parallel, dose-finding study in comparison with open la... | 2007-10-19 | due-trials |
| Reported results | 2005-003228-20 | A PHASE II, MULTI-CENTER, OPEN-LABEL STUDY OF YM155 IN SUBJECTS WITH HORMONE REFRACTORY PROSTATE CANCER (HRPC) PREVIOUSLY TREATED WITH AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN | 2007-03-30 | due-trials |
| Reported results | 2005-003367-23 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis | 2007-04-23 | due-trials |
| Reported results | 2005-004094-25 | A phase IIIb randomized study of intermittent versus continuous androgen deprivation therapy using ELIGARD 22.5 mg 3-month depot in subjects with relapsing and locally advanced prostate cancer who... | 2013-05-09 | due-trials |
| Reported results | 2005-004195-20 | A Phase 3, Multi-Center, Open Label Safety Study of RSD1235 in Subjects with Atrial Fibrillation. | 2007-01-03 | due-trials |
| Reported results | 2005-004988-27 | A PHASE II, MULTICENTRE, RANDOMISED, OPEN-LABEL, ACTIVE CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MICAFUNGIN SALVAGE MONO THERAPY VERSUS ACTIVE CONTROL INTRAVENOUS SALVAGE MONO THERAP... | 2008-09-12 | due-trials |
| Reported results | 2005-005546-39 | SOLIFENACIN SUCCINATE IN A FLEXIBLE DOSE REGIMEN WITH SIMPLIFIED BLADDER TRAINING VERSUS SOLIFENACIN SUCCINATE IN A FLEXIBLE DOSE REGIMEN ALONE IN A PROSPECTIVE, RANDOMIZED, PARALLEL GROUP, OVERACTIVE... | 2007-06-06 | due-trials |
| Reported results | 2005-005714-20 | A LONG-TERM FOLLOW UP STUDY TO EVALUATE THE SAFETY AND EFFICACY IN TRANSPLANT RECIPIENTS TREATED WITH MODIFIED RELEASE TACROLIMUS, FK506E (MR4); BASED IMMUNOSUPPRESSION REGIMEN | 2009-10-07 | due-trials |
| Reported results | 2006-000936-28 | A MULTICENTER, OPEN, SINGLE SEQUENCE CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF A TACROLIMUS MODIFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN STABLE LIVER TRANSPLANT PATIEN... | 2007-11-01 | due-trials |
| Reported results | 2006-000937-37 | A MULTICENTER, OPEN, SINGLE SEQUENCE CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF A TACROLIMUS MODIFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN STABLE KIDNEY TRANSPLANT PATIE... | 2007-07-11 | due-trials |
| Reported results | 2006-002072-18 | A randomized, double-blind, parallel group, placebo controlled, multi center dose ranging study of solifenacin succinate 3 mg, 6 mg and 9 mg in combination with tamsulosin OCAS 0.4 mg compared with ... | 2007-10-25 | due-trials |
| Reported results | 2006-002584-70 | A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects | 2009-04-23 | due-trials |
| Exempt, with results | 2006-002738-39 | A Phase 1 Open-Label Study of the Pharmacokinetics of Tacrolimus Cream B 0.1% after Twice Daily Topical Administration in Adolescents (≥ 12 to ≤ 17 Years of Age ) with Psoriasis | not-yet-due | |
| Reported results | 2006-003868-59 | A Phase III,Double Blind, Randomized Study to evaluate safety and efficacy of BAL8557 versus Voriconazole for primary treatment of Invasive Fungal Disease Caused by Aspergillus species or other filame... | 2013-03-28 | due-trials |
| Reported results | 2006-003951-18 | A PHASE III, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BAL8557 VERSUS A CASPOFUNGIN FOLLOWED BY VORICONAZOLE REGIMEN IN THE TREATMENT OF CANDIDEMIA AND OTHER INVASIVE CANDI... | 2015-03-03 | due-trials |
| Reported results | 2006-004606-97 | A MULTICENTER, SINGLE-ARM, OPEN, CONVERSION STUDY FROM A CYCLOSPORINE (CyA) BASED IMMUNOSUPPRESSIVE REGIMEN TO A TACROLIMUS MODFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRA... | 2009-10-07 | due-trials |
| Completed, but no date, and reported results Terminated | 2006-004761-34 | A Phase 2, Double-Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety, Tolerability and Pharmacodynamics of YM150 in Subjects with Non-Valvular Atrial Fibrillation. | bad-data | |
| Reported results | 2006-005003-33 | Estudio abierto de Isavuconazol en el tratamietno de pacientes con aspergilosis y deterioro de la función renal o de pacientes con enfermedad fúngica invasiva causada por mohos atípicos, levaduras u h... | 2016-05-05 | due-trials |
| Ongoing | 2006-005275-18 | Therapy-optimizing pilot study to investigate the efficacy and safety of an induction therapy with Campath-1H in combination with Tacrolimus for prevention of acute and chronic rejection in patients a... | not-yet-due | |
| Reported results | 2006-005523-42 | A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg once daily) against Placebo and Oxybutynin Hydrochloride (5 ... | 2011-04-12 | due-trials |
| Reported results | 2006-006462-42 | A PHASE IV, OPEN LABEL, PILOT STUDY OF THE TREATMENT OF CHILDREN WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD) USING LOCOBASE REPAIR® AS AN ADJUNCTIVE TO STANDARD TREATMENT | 2008-09-16 | due-trials |
| Reported results | 2007-001150-87 | A Phase 2, Double-Blind, Double-Dummy, Randomized, Parallel Group Dose Finding Study to Investigate the Safety and Tolerability of YM150 in Subjects with Non-Valvular Atrial Fibrillation and to Compar... | 2010-10-04 | due-trials |
| Reported results | 2007-001268-57 | A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multi-Center Study to Evaluate the Safety of the Co-administration of Solifenacin Succinate with 0.4 mg Tamsulosin Hydrochlorid... | 2008-08-19 | due-trials |
| Reported results | 2007-001451-19 | A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multi-center Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Sy... | 2009-03-24 | due-trials |
| Reported results | 2007-001452-39 | A Randomized, Double-Blind, Parallel Group, Active Controlled, Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symp... | 2010-05-06 | due-trials |
| Reported results | 2007-001661-15 | A Phase 2, Randomized, Double Blind, Placebo Controlled, Dose Escalation Study to Assess the Safety and Effects of Intravenous Conivaptan on the Hepatic Hemodynamic Response in Stable Euvolemic or Hyp... | 2008-11-06 | due-trials |
| Reported results | 2007-002092-14 | Efficacy and safety of Alefacept in combination with Tacrolimus, Mycophenolate Mofetil and Steroids in de-novo kidney transplantation - a multicenter, randomized, double-blind, placebo controlled, par... | 2009-09-18 | due-trials |
| Reported results | 2007-002114-19 | A phase II, randomized, double-blind, parallel-group, placebo-controlled, 12-week treatment, adaptive proof-of-principle study of twice daily oral dosing of a novel PDE4 inhibitor (ASP9831) in subject... | 2010-10-08 | due-trials |
| Completed, but no date, and reported results Terminated | 2007-004938-16 | A RANDOMISED, DOUBLE-BLIND STUDY TO COMPARE THE EFFECT ON SYMPATHETIC ACTIVITY AND HEMODYNAMIC PROFILE OF BARNIDIPINE AND AMLODIPINE IN PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION. | bad-data | |
| Reported results | 2007-005376-13 | A MULTICENTER, FOUR ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN A PROGRAF-/ ADVAGRAF-BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT SUBJECTS. Protocol for ... | 2010-03-02 | due-trials |
| Reported results | 2008-001211-37 | A randomized, double-blind, parallel group, placebo controlled, multi-center study of fixed dose combinations of solifenacin succinate (6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg and tam... | 2011-03-01 | due-trials |
| Reported results | 2008-001212-20 | AN OPEN-LABEL, LONG TERM, MULTI-CENTER STUDY TO ASSESS THE SAFETY AND EFFICACY OF FIXED DOSE COMBINATIONS OF SOLIFENACIN SUCCINATE (6 MG AND 9 MG) WITH TAMSULOSIN HYDROCHLORIDE OCAS 0.4 MG, IN MALE SU... | 2011-12-14 | due-trials |
| Reported results | 2008-002231-32 | A MULTICENTER, THREE ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY TO COMPARE RENAL FUNCTION IN LIVER TRANSPLANT RECIPIENTS RECEIVING AN IMMUNOSUPPRESSIVE REGIMEN OF ADVAGRAF® (IMMEDIATELY OR DELAYED PO... | 2013-01-04 | due-trials |
| Reported results | 2008-004416-13 | A Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Compare YM150 bid and qd Doses and Enoxaparin for Prevention of Venous Thromboembolism in Subjects Undergoing Elective Hip Replacement... | 2010-10-20 | due-trials |
| Reported results | 2008-005214-49 | Estudio abierto, aleatorizado, de no inferioridad de Micafungina versus el tratamiento estándar para la prevención de la enfermedad fúngica invasiva en pacientes de alto riesgo receptores de un traspl... | 2012-08-20 | due-trials |
| Reported results | 2008-005215-17 | A Study to Evaluate the Overall Effect of Solifenacin 5mg and 10mg on Bladder Wall Thickness and urinary Nerve Growth Factor in Female Subjects with Overactive Bladder and a Diagnosis of Detrusor Over... | 2011-06-23 | due-trials |
| Completed, but no date, and reported results Terminated | 2008-005830-63 | A Phase 2, Single-Arm Study to Evaluate the Safety and Pharmacokinetics of Alefacept in Adolescent Subjects with Moderate to Severe Psoriasis | bad-data | |
| Reported results | 2008-005972-29 | A Randomized, Double-Blind, Placebo Controlled Multi-Center and Parallel Group Study of the Safety, Tolerability and Efficacy of YM150 in combination with Standard Treatment in Secondary Prevention of... | 2011-02-24 | due-trials |
| Reported results | 2008-006409-18 | An Exploratory Study to Compare the Efficacy and Safety of Micafungin as a Pre-emptive Treatment of Invasive Candidiasis versus Placebo in High Risk Surgical Subjects - A Multicentre, Randomized, Doub... | 2012-08-23 | due-trials |
| Reported results | 2008-007087-42 | A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (25 mg qd and 50 mg qd) in Subjects with Sym... | 2010-04-27 | due-trials |
| Reported results | 2009-010319-34 | A Phase 1/2 Study Evaluating Intermittent and Continuous OSI 906 and Weekly Paclitaxel in Patients with Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) Studio di fase I/II per la valut... | 2014-03-01 | due-trials |
| Reported results | 2009-010777-20 | A Phase II, Multicenter, Open-Label Study Of YM155 Plus Rituximab In Previously Treated Subjects With CD20-Positive B Cell Non-Hodgkin’s Lymphoma Who Are Ineligible For Or Have Previously Received An ... | 2015-06-23 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2009-012258-19 | A Multicentre, Open-label, Pharmacokinetic Study of Modigraf® (Tacrolimus granules) in de novo Paediatric Allograft Recipients. | 2015-02-03 | bad-data |
| Reported results | 2009-012259-21 | A Long-term, Open-label, Non-comparative Study to Evaluate the Safety and Efficacy of a Modigraf® Based Immunosuppression Regimen in Paediatric Solid Allograft Recipients. | 2017-10-31 | due-trials |
| Reported results | 2009-012439-14 | A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects with HER2 Negative Metastatic Breast Cancer | 2013-06-27 | due-trials |
| Reported results | 2009-012820-97 | A Randomized, Double-Blind Placebo-Controlled Phase 3 Study of OSI-906 in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma | 2012-10-08 | due-trials |
| Reported results | 2009-013881-25 | Phase 2b, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12-Week Treatment with ASP1941 in Combina... | 2011-04-01 | due-trials |
| Reported results | 2009-015738-31 | A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects with Stage III (Unresectable) or Stage IV Melanoma | 2012-08-14 | due-trials |
| Reported results | 2009-016457-18 | A Multicentre, Single-Arm, Open-Label Study Of The Repeated Administration Of QUTENZA For The Treatment Of Peripheral Neuropathic Pain | 2013-09-26 | due-trials |
| Reported results | 2009-016458-42 | A Randomized, Controlled, Long-term Safety Study Evaluating the Effect of Repeated Applications of QUTENZA plus Standard of Care versus Standard of Care alone in Subjects with Painful Diabetic Perip... | 2014-02-27 | due-trials |
| Reported results | 2009-017197-21 | A multicenter, open-label, single ascending dose study to evaluate pharmacokinetics, safety and tolerability of solifenacin succinate suspension in pediatric patients aged 5 to 17 years (inclusive) wi... | 2011-08-14 | due-trials |
| Reported results | 2010-018739-17 | A Randomized, Placebo-controlled, Double-blind Phase 2 Study of Second-line Treatment with OSI-906 in Patients with Advanced Hepatocellular Carcinoma (HCC) after Failure of First-line Treatment with S... | 2011-11-29 | due-trials |
| Reported results | 2010-019638-28 | INVESTIGATING NEW ONSET DIABETES MELLITUS IN KIDNEY TRANSPLANT RECIPIENTS RECEIVING AN ADVAGRAF-BASED IMMUNOSUPPRESSIVE REGIMEN WITH OR WITHOUT CORTICOSTEROIDS ? A MULTICENTER, TWO ARM, RANDOMIZED, O... | 2013-05-22 | due-trials |
| Reported results | 2010-019639-37 | A MULTICENTER, TWO ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY INVESTIGATING RENAL FUNCTION IN AN ADVAGRAF-BASED IMMUNOSUPPRESSIVE REGIMEN WITH OR WITHOUT SIROLIMUS IN KIDNEY TRANSPLANT SUBJECTS | 2013-09-18 | due-trials |
| Reported results | 2010-019859-21 | A PHASE II, OPEN LABEL, PARALLEL GROUP, MULTI-CENTER STUDY TO COMPARE THE PHARMACOKINETICS OF TACROLIMUS IN ADULT SUBJECTS UNDERGOING PRIMARY ALLOGRAFT TRANSPLANTATION RECEIVING AN ADVAGRAF OR PROGRAF... | 2013-11-15 | due-trials |
| Reported results | 2010-020601-32 | A Randomized, Double-Blind, Factorial, Parallel-Group, Active and Placebo-Controlled, Multicenter Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Six Dose Combinations of Solif... | 2012-06-28 | due-trials |
| Reported results | 2010-020916-12 | A Randomized, Double-Blind, Placebo-controlled Phase 2 Study of Maintenance OSI 906 plus Erlotinib (Tarceva®), or Erlotinib plus Placebo in Patients with Nonprogression Following Four Cycles of 1st-li... | 2013-10-31 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2010-020925-42 | A Phase II, Open-Label, Multi-Center Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted from a Prograf® Based Immunosuppressive Regimen to a Tacroli... | 2016-10-28 | bad-data |
| Reported results | 2010-021075-89 | A MULTICENTER, THREE ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY TO COMPARE RENAL FUNCTION IN LIVER TRANSPLANT RECIPIENTS RECEIVING AN IMMUNOSUPPRESSIVE REGIMEN OF ADVAGRAF® (IMMEDIATELY OR DELAYED PO... | 2013-01-04 | due-trials |
| Reported results | 2010-021287-16 | A phase 2, open-label, single-arm, efficacy and safety study of MDV3100 in patients with hormone-naïve prostate cancer | 2017-05-02 | due-trials |
| Reported results | 2010-021868-15 | A Randomized, Double-Blind, Phase II, Efficacy and Safety Study of MDV3100 (ASP9785) vs. Bicalutamide in Castrate Men with Metastatic Prostate Cancer | 2017-11-08 | due-trials |
| Reported results Terminated | 2010-022941-72 | A MULTICENTER, TWO ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY TO COMPARE RENAL FUNCTION IN STABLE HEART TRANSPLANT RECIPIENTS RECEIVING AN ADVAGRAF® BASED IMMUNOSUPPRESSIVE REGIMEN WITH OR WITHOUT EVE... | 2012-10-08 | due-trials |
| Reported results | 2010-023258-34 | Tolerability of QUTENZA(TM) when applied after pre-treatment with lidocaine or tramadol in subjects with peripheral neuropathic pain – A randomized, multi-center, assessor-blinded study | 2012-04-25 | due-trials |
| Exempt, with results Terminated | 2010-023382-22 | Phase I/II, multi-center, open label study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of ASP9521 in patients with metastatic castrate-resistant pros... | 2012-10-03 | not-yet-due |
| Reported results | 2010-023775-25 | A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinet... | 2013-02-26 | due-trials |
| Reported results | 2011-000078-80 | A Phase II, Parallel Group, Randomized, Multicentre, Open Label Study to Compare the Pharmacokinetics of Tacrolimus in De Novo Pediatric Allograft Recipients Treated with an Advagraf or Prograf Based ... | 2021-04-21 | due-trials |
| Exempt, with results | 2011-000250-28 | A Multicenter, Open-label, Single-dose Study to Evaluate Pharmacokinetics, Safety and Tolerability of Solifenacin Succinate Suspension in Pediatric Subjects from 5 to less than 18 years of age with Ne... | 2012-08-13 | not-yet-due |
| Listed as ongoing, but also has a completion date and reported results | 2011-000330-11 | A Phase 3, Open-Label, Baseline-controlled, Multicenter, Sequential Dose Titration Study to Assess the Long-Term Efficacy and Safety, and the Pharmacokinetics of Solifenacin Succinate Suspension in Pa... | 2016-06-28 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2011-002047-10 | An Open-Label, Long-Term Extension, Multi-center, Sequential Dose Titration Study to Assess Safety and Efficacy of Solifenacin Succinate Suspension in Pediatric Subjects with Overactive Bladder (OAB) | 2014-10-24 | bad-data |
| Reported results | 2011-002066-20 | A Phase 3, Double-Blind, Randomized, Multi-center, Placebo-Controlled Sequential Dose Titration Study to Assess Efficacy, Safety and Population Pharmacokinetics of Solifenacin Succinate Suspension in ... | 2014-01-02 | due-trials |
| Reported results | 2011-003502-24 | A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination with mFOLFOX6 with Bevacizumab in Combination with mFOLFOX6 in Stage IV Metastatic Corectal Cancer (mCRC) Subjec... | 2015-01-07 | due-trials |
| Reported results | 2011-004555-39 | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokineti... | 2014-03-18 | due-trials |
| Reported results | 2011-005285-38 | A randomized Phase II multicenter, Open Label Study Evaluating the Efficacy and Safety of IMAB362 in Combination with the EOX (Epirubicin, Oxaliplatin, Capecitabine) regimen as First-Line Treatment o... | 2019-01-31 | due-trials |
| Reported results | 2011-005408-13 | A Phase 2, Randomized, Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | 2015-03-12 | due-trials |
| Reported results | 2011-005713-37 | A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects with Overactive Bladder (OAB) Treated with Antimusc... | 2013-04-25 | due-trials |
| Reported results | 2011-005872-41 | QUTENZA versus pregabalin in subjects with peripheral neuropathic pain: an open-label, randomized, multicenter, noninferiority efficacy and tolerability study | 2013-09-26 | due-trials |
| Reported results | 2011-006018-15 | A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Sub... | 2014-02-11 | due-trials |
| Reported results | 2011-006020-20 | A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Sub... | 2013-12-02 | due-trials |
| Reported results | 2011-006021-23 | A Phase 2, Open-Label, Non-Comparative, Multi-Center Extension Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis ... | 2016-03-25 | due-trials |
| Completed, but no date, and reported results Terminated | 2012-000101-69 | An exploratory, open label, single-arm study to evaluate the effect of Eligard® 6-month on biomarkers of disease in patients with metastatic prostate cancer. Een verkennend, open-label, enkel-arm o... | bad-data | |
| Reported results | 2012-000531-88 | A Phase IIIb/IV Randomized, Controlled, Double-blind, Double-dummy, Parallel Group Study to Compare the Efficacy of Fidaxomicin to Vancomycin in the Sustained Clinical Cure of Clostridium Difficile In... | 2013-04-16 | due-trials |
| Reported results | 2012-000780-24 | A Phase 3, Randomized, Double-Blind, Multi-Center Study to Compare the Efficacy and Safety of Micafungin Versus Amphotericin B Deoxycholate for the Treatment of Neonatal Candidiasis | 2014-12-15 | due-trials |
| Reported results | 2012-002791-14 | A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Dose-Response Relationship of ASP1707 in Subjects with Endometriosis Associated Pelvic Pain for 12 Wee... | 2015-07-30 | due-trials |
| Reported results | 2012-003178-22 | A Phase 3, Open-Label, Baseline-controlled, Multi-center, Sequential Dose -Titration Study to Assess the Pharmacokinetics, Long-Term Efficacy and Safety of Solifenacin Succinate Suspension in Children... | 2015-12-18 | due-trials |
| Reported results | 2012-005180-27 | A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis Studio di fase 3, ... | 2017-11-01 | due-trials |
| Reported results | 2012-005401-41 | A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects who have Received Solifenacin for 4 Weeks and Warrant... | 2014-11-25 | due-trials |
| Reported results | 2012-005735-91 | A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron... | 2015-10-22 | due-trials |
| Reported results | 2012-005736-29 | A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate with Mirabegron Compared to Soli... | 2016-09-08 | due-trials |
| Listed as ongoing, but also has a completion date | 2013-000093-29 | A Phase 2, Multicenter, Open-label Study to Assess the Efficacy and Safety of Enzalutamide with Trastuzumab in Subjects with HER2+ AR+ Metastatic or Locally Advanced Breast Cancer | 2024-01-30 | bad-data |
| Reported results | 2013-000464-29 | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an... | 2020-11-05 | due-trials |
| Reported results | 2013-000508-40 | A Phase 3, Multicenter, Investigator-blind, Randomized, Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h, and Vancomycin Oral Liquid or ... | 2018-03-07 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2013-000903-18 | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergo... | 2022-03-01 | bad-data |
| Reported results | 2013-000951-42 | A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis | 2019-11-15 | due-trials |
| Reported results Terminated | 2013-000985-13 | A MULTICENTRE, SINGLE-ARM, OPEN-LABEL STUDY TO CHARACTERISE THE RELATIONSHIP BETWEEN PRE-TRANSPLANT PHARMACOKINETICS OF ADVAGRAF® AND THE DOSE REQUIRED POST-TRANSPLANT TO ACHIEVE TARGET TROUGH LEVELS... | 2013-10-31 | due-trials |
| Reported results | 2013-001497-16 | A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in End Stage Renal Disease Subjects on Stable Dialys... | 2018-07-06 | due-trials |
| Reported results | 2013-002271-17 | A Multi-center, Single Arm Study of Enzalutamide in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer Previously Treated With Abiraterone Acetate | 2017-09-29 | due-trials |
| Reported results | 2013-002521-27 | A Phase 2a Enriched Enrollment Randomized Withdrawal Study to Assess Analgesic Efficacy and Safety of ASP8477 in Subjects with Peripheral Neuropathic Pain | 2015-02-13 | due-trials |
| Reported results | 2013-003022-92 | A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide... | 2019-01-11 | due-trials |
| Reported results | 2013-004076-34 | A phase II open-label rollover study for subjects that have participated in a linsitinib trial Badanie otwarte fazy II typu “rollover”, stanowiące kontynuację badania dla uczestników biorących udzi... | 2016-12-22 | due-trials |
| Reported results | 2013-004619-31 | A phase IIIb/IV randomized, controlled, open label, parallel group study to compare the efficacy of vancomycin therapy to extended duration fidaxomicin therapy in the sustained clinical cure of Clostr... | 2016-07-18 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2013-004711-50 | A Randomized, Double-Blind, Placebo-Controlled, Phase IIIb Study of the Efficacy and Safety of Continuing Enzalutamide in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Patients Tr... | 2024-05-31 | bad-data |
| Reported results | 2014-000340-15 | A multicentre, open-label, single ascending dose Phase 1 study to evaluate the pharmacokinetics, safety and tolerability of mirabegron OCAS tablets in pediatric subjects from 5 to less than 18 years o... | 2015-09-21 | due-trials |
| Reported results | 2014-001446-24 | A Phase 1, Single Dose, 4-Period Crossover Study to Assess the Bioavailability of an Mirabegron Oral Suspension Relative to the Mirabegron Prolonged Release Tablet and to Assess the Effect of Food on ... | 2015-01-22 | due-trials |
| Exempt, with results | 2014-002217-31 | A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia | 2018-03-07 | not-yet-due |
| Reported results | 2014-002349-23 | A Phase 2, Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme inhibitor (ACEi) or Angiotensin Receptor... | 2017-03-15 | due-trials |
| Reported results | 2014-003002-32 | Open label study to evaluate the pharmacokinetics of fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects with Clostridium difficile Infection (CDI) | 2016-10-24 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2014-004283-37 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects with Advanced Hepatocellular Carcinoma | 2021-02-09 | bad-data |
| Reported results | 2014-004996-22 | A Phase 2a, Randomized, Double-blind, Placebo- and Naproxen-controlled, Parallel-group Study to Assess the Analgesic Efficacy of ASP7692 in Patients with Pain Due to Osteoarthritis of the Knee | 2017-09-29 | due-trials |
| Listed as ongoing, but also has a completion date | 2015-000140-42 | A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation | 2017-04-05 | bad-data |
| Reported results | 2015-000700-26 | A multicentre, open-label, single dose, phase 1 study to evaluate the pharmacokinetics, safety and tolerability of mirabegron oral suspension in pediatric subjects from 3 to less than 12 years of age ... | 2016-09-30 | due-trials |
| Trial is outside EEC | 2015-001039-18 | Open-Label, Randomized, Comparative, Multi-Center Clinical Trial on the Therapeutic Effect of Tacrolimus (Prograf [Cap.]®) in Combination With Low-Dose Corticosteroid Compared With High-Dose Corticost... | bad-data | |
| Trial is outside EEC, and reported results | 2015-001040-11 | A Multicentre, Open-Label, Randomized, Controlled Study of Long-Term Intermittent Maintain Treatment with 0.03% Tacrolimus Ointment in Pediatric Patient with Moderate to Severe Atopic Dermatitis | bad-data | |
| Trial is outside EEC, and reported results | 2015-001041-83 | Clinical and Laboratory Evaluation of Acute Rejection, Myocyte Growth, Repair, and Oxidative Stress Following de novo Cardiac Transplant: A Comparison between Tacrolimus- and Cyclosporine- based Immun... | bad-data | |
| Ongoing | 2015-001790-41 | A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute ... | not-yet-due | |
| Reported results | 2015-002876-25 | An Open-label, Baseline-controlled, Multicenter, Phase 3 Dose-titration Study Followed by a Fixed-dose Observation Period to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Children an... | 2019-05-06 | due-trials |
| Trial is outside EEC, and reported results | 2015-002886-53 | A Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf® (tacrolimus)/MMF, and Extended Release (XL) Tacrolimus /MMF in de novo Kidney Transplant Recipie... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2015-002894-39 | An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Muta... | 2017-12-21 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2015-003869-28 | A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metast... | 2024-07-31 | bad-data |
| Reported results | 2015-004036-36 | A Phase 4, Double-Blind, Randomized, Placebo-controlled, Multi- Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men with Overactive Bladder (OAB) Symptoms While Taking... | 2018-09-12 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-001061-83 | A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FL... | 2023-05-09 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2016-001643-39 | A Phase 2 Multicenter, Randomized, Double-Blind, Placebo- Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy fo... | 2024-02-19 | bad-data |
| Ongoing | 2016-001694-32 | A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | not-yet-due | |
| Completed, reported early | 2016-001767-37 | A Phase 3, Double blind, Randomized, Multicenter, Parallel Group, Placebo controlled Sequential Dose Titration Study to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Pediatric Subjec... | 2023-12-28 | not-yet-due |
| Reported results | 2016-004138-12 | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of F... | 2019-03-23 | due-trials |
| Other | 2017-000876-27 | ASPIRO: A Phase 1/2, Randomized, Open-Label, Ascending-Dose, Delayed-Treatment Concurrent Control Clinical Study to Evaluate the Safety and Efficacy of AT132, an AAV8-Delivered Gene Therapy in X-Link... | not-yet-due | |
| Other | 2017-002566-50 | A Phase 2 Study of IMAB362 as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose T... | not-yet-due | |
| Other | 2017-002567-17 | A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Posit... | not-yet-due | |
| Ongoing, reported early | 2017-003344-21 | An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) | not-yet-due | |
| Reported results | 2017-003693-13 | A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2a, Proof-of-Concept Study of ASP8302 in Subjects with Underactive Bladder | 2020-04-28 | due-trials |
| Listed as ongoing, but also has a completion date | 2018-000519-26 | A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) ... | 2021-10-14 | bad-data |
| Other | 2018-002301-61 | A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation and Expansion Study of Gilteritinib (ASP2215) Combined with Chemotherapy in Children, Adolescents and Young Adults with FMS-like Tyros... | not-yet-due | |
| Other | 2018-002551-15 | A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment i... | not-yet-due | |
| Completed, but no date, and reported results | 2018-002924-18 | A Phase 1 Crossover Study to Assess the Relative Bioavailability of Roxadustat Following a Single Dose of Pediatric Azo Dye-free Tablet and Pediatric Azo Dye free Mini-tablet (Solid and Suspension) Co... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2018-003528-35 | A Phase 3, Randomized, Placebo-controlled, 12-week Double-blind Study, followed by a Non-Controlled Extension Treatment Period, to Assess the Efficacy and Safety of Fezolinetant in Women Suffering fro... | 2021-08-11 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-003529-27 | A Phase 3, Randomized, Placebo-controlled, 12-week Double-blind Study, followed by a Non- Controlled Extension Treatment Period, to Assess the Efficacy and Safety of Fezolinetant in Women Suffering fr... | 2021-04-23 | bad-data |
| Trial is outside EEC, and reported results | 2018-003867-79 | Astagraf XL® to Understand the Impact of Immunosuppression on De Novo DSA Development and Chronic Immune Activation in Kidney Transplantation | bad-data | |
| Trial is partly outside EEC, and reported results | 2018-003975-36 | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis ... | 2023-03-20 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2019-000275-16 | A Randomized, Placebo-controlled, Double-blind Phase 3 Clinical Study to Investigate the Long-Term Safety of Fezolinetant in Women Suffering from Vasomotor Symptoms (Hot Flashes) Associated with Menop... | 2022-01-04 | bad-data |
| Trial is outside EEC, and reported results | 2019-004503-12 | A Phase 1, Randomized, Single Dose, Blinded, Dose-Escalation Study to Assess Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Compariso... | bad-data | |
| Trial is outside EEC, and reported results | 2019-004930-41 | A Phase 1, Open-Label, Multicenter, Non-comparative Pharmacokinetics and Safety Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2021-001685-38 | A Phase 3b, Randomized, Double-blind, Placebo-controlled, 24-week Study to Assess the Efficacy and Safety of Fezolinetant in Menopausal Women Suffering from Moderate to Severe Vasomotor Symptoms (Hot ... | 2023-06-20 | bad-data |
| Other | 2021-005455-37 | A Phase 3, Open Label, Multicenter, Baseline-Controlled Sequential Dose Titration Study Followed by a Fixed Dose Observation Period to Evaluate Pharmacokinetics, Efficacy and Safety of Mirabegron Prol... | not-yet-due | |
| Trial is outside EEC, and reported results | 2022-002350-68 | A Multicenter, Open-label, Non-comparative Study of Modigraf® (Tacrolimus Granules) to Evaluate the Pharmacokinetics and Long-term Safety and Efficacy in De Novo Pediatric Allograft Liver and Kidney T... | bad-data | |
| Trial is outside EEC, and reported results | 2022-002351-19 | A Long-term, Open-label, Non-comparative Study to Evaluate the Safety and Efficacy of a Modigraf® Based Immunosuppression Regimen in De Novo Pediatric Allograft Liver and Kidney Transplantation Recipi... | bad-data | |
| Other | 2022-002860-59 | An Open-label Extension (OLE) Phase 3 Trial to Assess the Safety of Intravitreal Administration of avacincaptad pegol (Complement C5 Inhibitor) in Patients with Geographic Atrophy Who Previously Compl... | not-yet-due |